v3.26.1
Segments (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment.


Three Months Ended March 31,
20262025
Program expenses(1)
Atebimetinib (IMM-1-104)$4,055,258 $4,257,936 
Envometinib (IMM-6-415)4,345 1,623,755 
Other programs2,019,865 1,242,109 
Non-program expenses(2)
1,469,553 1,204,385 
Employee-related costs6,067,936 5,378,938 
Stock-based compensation expense1,636,675 1,692,267 
Depreciation and amortization81,402 85,261 
Other segment items(3)
(1,874,139)(438,519)
Net loss$13,460,895 $15,046,132 

(1) Includes direct research and development expenses.
(2) Includes general and administrative expenses, in addition to facilities and other research and development expenses.
(3) Includes interest income and other (income) expense.